Decnupaz Approved for Rare Blood Cancer

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting

Decnupaz Approved for Rare Blood Cancer

(MedPage Today) -- The FDA approved the antibody-drug conjugate pivekimab sunirine (Decnupaz) for the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval stipulates use of the drug in adults. Although...

FDA Approves AbbVie’s ADC for Rare Blood Cancer; Delays Decision on AstraZeneca’s Oral SERD for Breast Cancer

**FDA Action on Cancer Treatments: AbbVie Receives Appr […] The post FDA Approves AbbVie’s ADC for Rare Blood Cancer; Delays Decision on AstraZeneca’s Oral SERD for Breast Cancer first appeared on GeneOnline News. The post FDA Approves AbbVie’s ADC for Rare Blood Cancer; Delays Decision on AstraZeneca’s Oral SERD for Breast Cancer appeared first on GeneOnline News.

FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology

AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.